Seattle Genetics Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St set to open lower as Trump says Iran deal is 'over'
- Oil jumps around 5% to two-week high after Trump warns of more attacks on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Seattle Genetics (SGEN) Tops Q2 EPS by 51c, Revenues Beat; Offers FY20 Revenue Guidance
July 30, 2020 4:16 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q2 EPS of ($0.12), $0.51 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $278 million versus the consensus estimate of $256.43 million.
PRODUCT SALES SUMMARY
ADCETRIS: Continued growth with net sales in the U.S. and Canada of $167.5 million in the second quarter of 2020, an increase of five percent over the second quarter of 2019.PADCEV: U.S. net sales in the... More